Compounded GLP-1
Also called compounded semaglutide, compounded tirzepatide, research-grade GLP-1.
By Dr Chad Okay4 min read
Compounded GLP-1 medications are versions of semaglutide or tirzepatide produced by compounding pharmacies, not the original manufacturers (Novo Nordisk, Eli Lilly). They're cheaper, often sold online or via 'wellness' clinics, and have been used to fill supply gaps. Quality, sterility and dose accuracy vary widely. Multiple deaths and serious injuries have been linked to compounded GLP-1s. UK MHRA does not authorise this route. Avoid.
Why compounded GLP-1 exists
Branded GLP-1s have been in supply shortage since 2022. In the US, FDA rules allow compounding pharmacies to produce alternative versions of drugs on the official shortage list. This created a large grey market for cheaper compounded semaglutide and tirzepatide, often via online clinics with minimal medical oversight. As supply eased in 2025, FDA started restricting compounding again, but the market has not fully shut down.
What goes wrong
- Active ingredient may not be the same molecule. Some products use semaglutide salts (acetate, sodium) which are not the same as branded sodium salt and have different absorption profiles.
- Contamination risk: endotoxin was detected in all online semaglutide samples in one published analysis (2.16 to 8.95 EU/mg).
- Dose accuracy: independent testing of online semaglutide products found total content exceeding the labelled amount by roughly 28-39%, with purity far below the 99% claimed.
- Source of active pharmaceutical ingredient: often imported from unregulated suppliers in China or India.
- No real-world adverse event monitoring.
- Mixed with B12 or other additives the user is not informed about.
Reported harms
- FDA: hundreds of adverse event reports involving compounded GLP-1s through 2024-2025.
- Multiple severe overdoses requiring hospitalisation.
- Deaths linked to dosing errors and contamination.
- Bacterial infections at injection sites.
- Higher reporting of abdominal pain, diarrhoea and nausea in compounded users versus non-compounded products in pharmacovigilance data.
What about UK availability
- MHRA does NOT authorise compounded versions of branded medicines for general use.
- UK pharmacies cannot legally sell compounded semaglutide or tirzepatide as substitutes for Ozempic, Wegovy or Mounjaro.
- Online sellers offering 'research peptides' or 'unlicensed semaglutide' are operating outside MHRA.
- Importing compounded GLP-1 from US compounding pharmacies for personal use is technically not legal and not safe.
How to get GLP-1 safely
- NHS pathway: ask your doctor about referral to specialist Tier 3 weight-management or diabetes services.
- Private clinic with MHRA-registered prescribers: typical cost £150-300/month including consultations.
- Branded products only: Ozempic, Wegovy, Mounjaro.
- Pharmacist-supplied on a doctor's or specialist prescription.
- Verify the prescriber is GMC-registered. Verify the pharmacy is GPhC-registered.
If you have already used one
Feeling unwell after injecting a compounded or unlicensed product deserves urgent medical help, with the product and its packaging brought along, and shakiness, sweating or confusion can mean a dosing error that needs treating straight away. Report the product and any reaction (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US: reports are how regulators find dangerous batches), and tell your own doctor what you have taken, even if it was bought without a prescription. They cannot help with what they do not know about, and they have heard worse.
Common questions
Sometimes the same molecule, sometimes a salt form that behaves differently in the body, sometimes contaminated. Even when it's the same active ingredient, sterility and dose accuracy are unreliable. Cheaper does not mean equivalent.
Sources
- 1FDA: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss (concerns with unapproved GLP-1 drugs, salt forms, dosing errors)U.S. Food and Drug Administration
- 2MHRA: UK medicines regulator warns against buying weight-loss medicines without a prescriptionMHRA / GOV.UK
- 3Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription (potency, purity, endotoxin findings)Journal of Medical Internet Research, 2024
- 4Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting systemExpert Opinion on Drug Safety, 2026
- 5UIC Drug Information Group: Safety concerns regarding compounded GLP-1 receptor agonists (FDA 520/480 adverse event reports, foreign APIs, 5-20x dosing errors)University of Illinois Chicago College of Pharmacy
- 6Teva announces FDA approval and launch of generic Saxenda (liraglutide injection), first generic GLP-1 indicated for weight lossTeva Pharmaceuticals
Related terms


